Comerț 4D Molecular Therapeutics Inc - FDMT CFD

Condiții de tranzacționare

• Tip:
  CFD

  

  Knock-out

  
• Ecart minim: 0.07
• Ajustarea finanțării peste noapte a poziției lungi: -0.02157%
• Ajustarea finanțării peste noapte a poziției scurte: -0.00065%
• Oră ajustare finanțare peste noapte: 21:00 (UTC)
• Monedă: USD
• Cantitate minimă tranzacționată: 1
• Marjă: 50.00%
• Bursă: United States of America
• Comision tranzacționare: 0%
• Prima de oprire garantată: 1%

Statistici cheie

• Închis anterior: 8.69
• Deschidere: 8.95
• Schimbare la 1 an: 121.53%
• Interval zi: 8.72 - 9.13

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.